Time is Brain
Time is Brain is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Time is Brain.
Time is Brain is a company.
Key people at Time is Brain.
Key people at Time is Brain.
Time is Brain (TIB) is a Barcelona-based health tech startup founded in 2020 that develops BraiN20®, a portable, non-invasive medical device likened to the "stroke ECG." It monitors the brain's N20 electrical signal in real-time using AI to analyze evoked potentials from electrodes placed on the head and hands, enabling faster diagnosis and treatment of acute ischemic stroke (AIS) patients[1][2][3][5][7]. The device serves neurologists, stroke units, and emergency teams by reducing time-to-treatment from 4 hours to 1 hour, enhancing endovascular thrombectomy (EVT) efficacy, detecting complications early, and predicting recovery—addressing the crisis where every minute post-stroke kills 1.9 million brain cells[2][3][5][6]. Currently in pre-industrialization after validation in Spanish hospitals like Germans Trias i Pujol and Bellvitge, TIB has raised €1.7M, boasts a €7.9M valuation, employs 12 people, and was selected for Ship2B's health acceleration program[1][2].
TIB emerged from research initiated in 2013 by neurologists at Hospital Germans Trias i Pujol (HGTP) in Barcelona, who sought better diagnostic tools for stroke's devastating impact. A clinical study from 2018-2020 (NCT04099615) discovered and validated the N20 biomarker in AIS, leading to the company's 2020 founding by Alicia Martínez (CEO, MD PhD, neurologist with 10+ years in electrodiagnostics), Antoni Dávalos (CSO, MD PhD, renowned stroke KOL and director of Catalonia's stroke programs), and Jaume Coll i Cantí (Scientific Advisor, MD PhD)[1][3][4]. The core team includes experts like COO Blas Díaz (medtech R&D), CTO Gisela Ruiz (PhD in electrochemical biosensors), QA/RA Oriol Vernis (25+ years in medical devices), and business leads with multinational experience. Early traction came from hospital pilots validating the tech, propelling TIB toward market readiness amid regulatory hurdles[1][2][3].
Time is Brain rides the AI-driven medtech wave in stroke care, where rapid diagnostics are critical amid rising global stroke incidence (projected 200M€ market)[2]. Timing aligns with post-COVID emphasis on endovascular therapies and real-time neuromonitoring, as aging populations strain healthcare—EVT windows are narrow, and current tools lack brain-specific visibility[2][3][5]. Market tailwinds include regulatory pushes for POCT devices and HTA assessments favoring outcome-improving tech. TIB influences the ecosystem by pioneering N20 as a biomarker, potentially standardizing stroke workflows, inspiring similar AI biosensor startups, and bridging academia (HGTP research) with commercialization via accelerators like Ship2B[1][2][3].
TIB is primed for global launch post-pre-industrialization, targeting EU/CE mark then US/FDA amid active market prep (KOL dissemination, reimbursement analysis)[3]. Trends like AI personalization in neurocritical care and portable diagnostics will accelerate adoption, with pilots scaling to international trials. Influence may evolve from niche innovator to stroke standard-setter, especially if BraiN20® proves prognostic power in larger studies—embodying "Time is Brain" by turning every saved minute into lives transformed, fulfilling its originators' 2013 quest[2][3][6].
